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A B S T R A C T
Small cell lung cancer (SCLC) is an extremely aggressive cancer that frequently recurs. Twenty-three human
SCLC lines were selected representing varied Myc status. Gene expression of lung cancer, stem-like, hedge-
hog pathway, and notch pathway genes were determined by RT2-PCR array and Exon 1.0 ST array. Etoposide
and topotecan concentration response was examined. The IC50’s for etoposide and topotecan ranged over
nearly 3 logs upon 96 hrs exposure to the drugs. Myc status, TOP2A, TOP2B and TOP1 mRNA expression
or topoisomerase 1 and topoisomerase 2 protein did not account for the range in the sensitivity to the
drugs. γ-secretase inhibitors, RO429097 and PF-03084014, had little activity in the SCLC lines over ranges
covering the clinical Cmax concentrations. MYC ampliﬁed lines tended to be more sensitive to the
bromodomain inhibitor JQ1. The Smo antagonists, erismodegib and vismodegib and the Gli antagonists,
HPI1 and SEN-450 had a trend toward greater sensitivity of the MYC ampliﬁed line. Recurrent SCLC is
among the most recalcitrant cancers and drug development efforts in this cancer are a high priority.
Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Small cell lung cancer (SCLC) is an extremely aggressive cancer
that frequently recurs after conventional cytotoxic chemotherapy.
SCLC cells are small with limited cytoplasm surrounding the nuclei.
The cells tend to grow as ﬂoating clusters or spheroids which are
often diﬃcult to disaggregate. While SCLC is challenging to work
with in culture, it tends to grow well as xenografts. SCLC is a lung
malignancy of neuroendocrine origin for which there is no effec-
tive treatment. It affects >200,000 people world-wide every year with
a very high mortality rate. In the US, 13–15% of lung cancer cases
are SCLC. Although initially a chemotherapy and radiation-sensitive
disease, SCLC recurs rapidly and <5% of patients survive ﬁve years.
There has been no change in the standard of care for SCLC for the
past three decades. Treatment most often involves platinum-
based combination chemotherapy, hyperfractionated thoracic
radiation, and prophylactic cranial irradiation [1,2]. SCLC has unique
biology and chromosomal changes, dysregulation of tumor sup-
pressor genes, oncogenes, and signaling pathways, upregulation of
receptor tyrosine kinases, growth factors and cellular markers, and
activation of early development pathways [3]. From 1977 through
1992, 126 SCLC cell lines were established from patients at the NCI-
Navy Medical Oncology Branch. Extensive clinical information was
available on 96 patients from whom these cell lines were estab-
lished. The number of SCLC lines established from previously
untreated patients with both limited and extensive stage SCLC in-
creased during the 16 years of the study. These cell lines became
and remain critically important models for the study of this deadly
malignancy [4].
MYC family DNA ampliﬁcation was present in 16/44 (36%) SCLC
lines established from previously treated patients compared to 7/52
(11%) SCLC lines established from untreated patients. MYC DNA am-
pliﬁcation is associated with shorter patient survival [4]. The
apoptosis related gene, caspase 8, is frequently silenced in SCLC by
aberrant promoter methylation. In 34 SCLC lines (12 MYC ampli-
ﬁed), caspase 8 gene and protein expression was lost in 79%. There
was also a high rate of loss of expression of CASP10, DR5, FAS and
FASL in SCLC. The loss of expression of proapoptotic components
was higher in MYC ampliﬁed SCLC lines and these lines were com-
pletely TRAIL resistant [5]. Array comparative genomic hybridization
(aCGH) karyotype analysis of 33 SCLC tumors and 13 SCLC lines
showed that SCLC tumor and line karyotypes were highly aber-
rant with high copy number gains detected in SCLC tumors and lines
in cytogenetic bands encoding JAK2, FGFR1 and MYC family
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members. The copy number of these genes often exceeded 100, sug-
gesting they represent driver alterations and drug targets in SCLC.
In SCLC tumors, recurrent copy number alterations were observed
in 203 genes. The aCGH proﬁle of SCLC lines and clinical SCLC speci-
menswere similar [6]. Despite the discovery of an increasing number
of MYC target genes, identiﬁcation of MYC target core sets corre-
sponding to speciﬁc cellular outcomes has proved elusive.
The highly aggressive nature of SCLC suggests that this disease
may have an elevated stem cell fraction. Side population cells from
the NCI-H146 or NCI-H526 SCLC lines over-expressed the follow-
ing genes associated with cancer stem cells and drug resistance:
CD133, ABCG2, FGF1, IGF1,MYC, SOX1/2,WNT1, angiogenesis genes,
and notch and hedgehog pathways [7,8]. Cancer may be viewed as
aberrant organogenesis in which progenitor/stem cells escape de-
pendence on niche signaling throughmutation in genes such as Ptch
or throughactivationof progenitor cell pathways.Normally, theairway
epithelial uses the hedgehog pathway to repopulate after injury. Ac-
tivation of the hedgehog pathway has been studied in amouse SCLC
model (mSCLC) in which Rb1 and Trp53 were deleted in the lung
epithelium.mSCLCexpressedhedgehogpathway components in vivo
and in culture. Crossing a constitutively active allele of the hedge-
hogpathwaymember, Smoothened (Smo), intoRb1-Trp53conditional
mutantmice led to an increase in the size andnumberof lungnodules
permousewhile Smodeletion resulted in fewer and smaller nodules.
Smo and Gli1 inhibitors blocked proliferation and increased death
inmSCLC. In vivo, Smo inhibition following cisplatin and etoposide
treatmentwas effective in preventing SCLC xenograft regrowth, sug-
gesting that hedgehog pathway inhibitors may be useful therapies
[9].Hedgehogacyltransferase (Hhat)-mediatedpalmitoylation, amod-
iﬁcation critical for hedgehog signaling, is a target for Shh pathway
inhibition. In cells, Hhat inhibitors blocked hedgehog palmitoylation
and inhibited autocrine and paracrine hedgehog signaling [10]. SCLC
is characterized by high levels of SOX2, SOX4, and SOX11. The HMG
box transcription factor SOX4 involved in neuronal development is
ampliﬁed and overexpressed in SCLC and may be a driver onco-
gene [11]. CD44highCD90+ cells from primary SCLC lines had
mesenchymal morphology, increased expression of mesenchymal
markersN-cadherin and vimentin, increasedmRNA levels of the em-
bryonic stem cell related genes Nanog and Oct4, suggesting the
CD44highCD90+ population a good candidate for the SCLC cancer
stem cells [12].
The current report examines gene expression and compound re-
sponse in a series of SCLC lines with a focus on their varied
expression of members of the MYC family.
Methods and materials
Cell lines
The twenty-three small cell lung carcinoma (SCLC) cell lines used in the study
were purchased from American Type Culture Collection (ATCC, Manassas, VA) and
Table 1
Shown are the morphology and doubling time for each SCLC line along with the patient prior treatment, response to treatment and Myc status.
Cell Line Morphology, Growth
Properties
Site of Origin Prior Radiation Prior Chemo Chemo Regimen Response Myc Doubling Time
(h)
NCI-H82 epithelial, suspension,
multi-cell aggregates
pleural effusion Y Y CMC/VAP, VP16 CR cMYC 25.5 ± 4.2
NCI-H211 suspension bone marrow Y Y CMC/VAP PR cMYC 55.6 ± 6.5
NCI-H446 epithelial, mixed
adherent & ﬂoaters
pleural effusion N Y CMC/VAP PR cMYC 41.0 ± 4.6
NCI-H524 suspension lymph node N Y CMC/VAP PR cMYC 38.4 ± 0.9
NCI-H1650 epithelial, adherent pleural effusion N N AD, PL PD cMYC 41.3 ± 3.3
NCI-H2171 ﬂoating clusters,
suspension
pleural effusion Y Y VP/PL PR cMYC 48.6 ± 6.7
NCI-H69 suspension, multi-cell
aggregates
pleural effusion Y Y CMC/VAP, VP16/iFOS CR N-MYC 51.1 ± 3.1
NCI-H526 epithelial, round
clusters in suspension
bone marrow N N CMC/VAP PD N-MYC 35.2 ± 1.7
NCI-H720 suspension atypical carcinoid Unknown Unknown Unknown Unknown N-MYC 72.4 ± 26.7
NCI-H378 epithelial, suspension,
multi-cell aggregates
pleural effusion Y Y CMC/VAP PR L-MYC 92.8 ± 12.9
NCI-H510 epithelial, , mixed
adherent & ﬂoaters
brain/adrenal Y Y CMC/VAP SD L-MYC 152.3 ± 40.6
NCI-H889 epithelial clusters in
suspension
lymph node N N VP/PL PR L-MYC 61.1 ± 5.1
NCI-H1963 suspension carcinoma N N VP/PL CR LMYC 43.6 ± 7.6
NCI-H2107 epithelial, clusters in
suspension
bone marrow N N VP/PL PR LMYC 63.4 ± 8.4
NCI-H128 ﬂoating aggregates pleural effusion Y Y CMC/VAP PR unamp 77.3 ± 16.9
NCI-H146 epithelial, suspension,
multi-cell aggregates
bone marrow N Y CMC/VAP PR unamp 52.9 ± 11.9
NCI-H187 suspension pleural effusion N N CAPO, MTX PR unamp 67.7 ± 13.6
NCI-H196 suspension pleural effusion Y Y CAPO, PCI CR unamp 80.1 ± 8.4
NCI-H345 epithelial, suspension,
multi-cell aggregates
bone marrow Y Y CMC/VAP CR unamp 65.3 ± 8.6
NCI-H740 suspension lymph node N N VP/PL PR unamp 79.7 ± 9.9
NCI-H841 mixed adherent &
ﬂoaters
lymph node Y Y CMC/VAP NR unamp 31.2 ± 3.6
NCI-H865 aggregate in
suspension
pleural effusion Y Y CMC/VAP CR unamp 80.9 ± 6.8
NCI-H1688 epithelial, adherent derived from liver met N N VP/PL PD unamp 82.7 ± 15.6
NCI-H1930 aggregate in
suspension
lymph node N N VP/PL CR unamp 147.4 ± 22.3
CMC/VAP: cyclophosphamide, methotrexate; AD:adriamycin; PL: cis-platinum; iFOS: ifosfamide; VP/Pl: VP16, cis-platinum; CAPO: cyclophosphamide, Adriamycin, cis-
platinum, vincristine; PCI: Prophylactic cranial irradiation; Response: CR: complete remission; PR: partial remission; PD: progressive disease; SD: stable disease; NR: No
response.
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Fig. 1. Panel A: Expression of genes associated with lung cancer and stem-like properties in 23 SCLC lines as determined by the 1/ΔCT value from RT-PCR or as log2 from
gene expression derived from exon arrays. The blue symbols represent c-MYC ampliﬁed SCLC lines (n = 5), green symbols represent n-MYC ampliﬁed SCLC lines (n = 3), red
symbols represent l-MYC ampliﬁed SCLC lines (n = 5) and gray symbols represents MYC unampliﬁed SCLC lines (n = 10). Panel Β: Western blot showing the expression of
c-myc, n-myc, l-myc and α-tubulin in the 23 SCLC lines.
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cultured in serum free RPMI1640 (Gibco®, Grand Island, NY) containing selenium,
insulin and transferrin or media supplemented with 5% fetal bovine serum (FBS,
Hyclone™, Utah, USA) and glutamine. Cells were maintained in a 5% CO2-humidiﬁed
incubator at 37 °C. Table 1 shows the morphology and doubling time for each cell
line along with the patient prior treatment and response to treatment.
Concentration response curves
NOTCH, BET-bromodomain, Hedgehog, glutamate and topoisomerase inhibi-
tors were obtained from the Drug Synthesis and Chemistry Branch of the
Developmental Therapeutics Program, National Cancer Institute (Rockville, MD). All
drugs dilutions were prepared at 1000× in DMSO and stored at −80 °C. Growth in-
hibition assays for small cell lung carcinoma cell lines to NOTCH, BET-bromodomain,
hedgehog, glutamate and topoisomerase inhibitors were performed in 96 well plates
using Tecan Robotic. Cells were exposed to eight drug concentrations for 96 hrs and
ATP content (CellTiter Glo®, Promega) was used as an end point. Luminescence was
measured using Tecan-100 microplate reader.
Combination concentration response
Carboplatin and etoposide concentration response curves were generated for the
SCLC lines. Based on the IC50 values for each compound, a suitable concentration
range for combination of the two agents was determined. The selected concentra-
tions were 3.7 μM carboplatin and 0.3 μM etoposide. The combination of etoposide
and carboplatin was treated as a single agent for the combination experiments. The
third agents were examined over a concentration range based around their clinical
Cmax concentration, if known. All compound exposures were simultaneous for 96 hrs
with ATP content (CellTiter Glo®, Promega) as the end point. Luminescence wasmea-
sured using Tecan-100 microplate reader.
RNA extraction and measurement of RNA integrity
RNA from the cell pellets was extracted using Qiagen miRNeasy Mini Kit
(#217004) with on column DNase digestion according to manufacturer’s instruc-
tions. The RNA integrity in terms of RIN numbers of extracted RNA was measured
on an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Samples with a RIN above
8.5 were used for gene expression proﬁling.
Real-time reverse transcription-Polymerase Chain Reaction (RT-PCR)
Gene expression of Hedgehog, Notch, lung cancer and stem like genes in 24 SCLC
cell lines was performed using 96 well custom RT2-PCR Array (Qiagen). A total of
800 ng RNA was used for cDNA synthesis and genomic DNA elimination using the
RT2 easy ﬁrst strand cDNA synthesis kit (Qiagen, Germantown, MD) as recom-
mended by themanufacturer. The qRT–PCRwas performed on an Applied Biosystems
7500 system using Fast SYBR green master mix (Qiagen), following the manufactu-
rer’s recommendations. Forty PCR cycles were run in a 96 well plate RT2-PCR array.
Gene expression values were normalized using housekeeping genes. Average values
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of each gene for 24 cell lines was subtracted from corresponding genes for each cell
line and gene expression is expressed as log 2 of the value as 2^-ΔΔCT.
Western blots
Untreated SCLC cells cultured in log phase were collected, washed with PBS and
cell pellets were stored at −70 °C. The cell pellets were lysed in sodium dodecyl sulfate
(SDS) lysis buffer and cell lysates were prepared as described (Ref). The protein con-
centrationswere determined by BCA Protein Assay Kit. Total proteins were fractionated
using SDS-polyacrylamide gel electrophoresis (PAGE) and transferred onto PVDFmem-
brane (Millipore, MA) for Western blot. Membranes were blocked with 5% nonfat
milk in TBST for 1 hr and then incubated overnight (16 hrs) with primary antibod-
ies on a rocker at 4 °C. The primary antibodies used were MYC antibody (CST, #5605,
1:750); MYCN antibody (SC, #56729, 1:200); MYCL antibody (SC, #790, 1:200); ASCL-1
antibody (SC, #390794, 1:500) and β-actin (Sigma, # 1:5000); TopoI antibody (BD
Pharmingen, #556597, 1:1000); TopoIIa antibody (CST, #4733, 1:1000). Primary an-
tibody was removed; membranes were washed three times with TBST for 5min each,
and probedwith corresponding secondary antibody (1:2000 dilution) for 1 hr at room
temperature. Finally, membranes were washed 3 times with TBST and developed
using visualizer western blot detection kit fromMillipore (Billerica, MA). Images were
captured using the Kodak Image Station 4000MM Pro and processed using Kodak
Molecular Imaging Software (Carestream Health, New Haven, CT, USA). The protein
levels were normalized by β-actin.
Exon arrays
Total RNAwas extracted from samples using QiagenmiRNeasyMini Kit (#217004)
to isolate RNA including the miRNA fraction, according to manufacturer’s instruc-
tions. Agilent RIN >8.5 indicated good quality RNA for all samples. Sense strand cDNA
from 100 ng total RNA was fragmented and labeled using Affymetrix WT terminal
labeling kit. Samples were hybridized with Human Exon 1.0 ST Arrays (Affymetrix)
at 45 °C, 60 rpm for 16 hrs. Arrays were washed and stained using Affymetrix Flu-
idics Station 450, and scanned on Affymetrix GeneChip scanner 3000 7G.
Results
Twenty-three human SCLC lines were selected for study to rep-
resent varied Myc status. Six lines had ampiﬁed c-Myc, three lines
had ampliﬁed n-Myc, ﬁve lines had ampliﬁed l-Myc and the re-
maining ten lines had no Myc ampliﬁcation. Fourteen lines were
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Fig. 3. Panel A: Expression of genes associated with the Notch pathway in 23 SCLC lines as determined by the 1/ΔCT value from RT-PCR or as log2 from gene expression
derived from exon arrays. The blue symbols represent c-MYC ampliﬁed SCLC lines (n = 5), green symbols represent n-MYC ampliﬁed SCLC lines (n = 3), red symbols repre-
sent l-MYC ampliﬁed SCLC lines (n = 5) and gray symbols represents MYC unampliﬁed SCLC lines (n = 10). Panel Β: Concentration response curves for the 23 SCLC lines
exposed to 0.001–10 μM of the γ-secretase inhibitors, RO429097 and PF-03084014, for 96 hrs. The blue symbols represent c-MYC ampliﬁed SCLC lines (n = 5), green symbols
represent n-MYC ampliﬁed SCLC lines (n = 3), red symbols represent l-MYC ampliﬁed SCLC lines (n = 5) and gray symbols represents MYC unampliﬁed SCLC lines (n = 10).
The dotted lines are the clinical Cmax for each compound. The experiments were repeated 3–4 times. Panel C: Concentration response curves for 4 representative SCLC
lines exposed to 0.01–20 μM of PF-03084014 alone (blue line) or in simultaneous combination with 3.7 μM carboplatin and 0.3 μM etoposide (red line). The gray line is
calculated simple Bliss additivity for the combination regimen.
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from patients who had prior chemotherapy and/or radiation therapy
and most lines were derived from samples of pleural effusion or
lymph node. The generation or doubling times of the cell lines ranged
from 25.5 hrs to 152 hrs (Table 1). Two NSCLC lines, A549 and NCI-
H1650, were used as comparators.
Gene expression of lung cancer, stem-like, hedgehog pathway,
and notch pathway genes were determined by RT2-PCR array and
Exon 1.0 ST array. There was good agreement between gene ex-
pression by RT-PCR and exon array. Most of the SCLC lines express
high levels of ASCL1 (Fig. 1A). Generally, the SCLC lines which were
c-Myc ampliﬁed were among the lowest ASCL1 mRNA expressers;
however, the ﬁve c-Myc ampliﬁed SCLC lines expressed ASCL1
protein at levels similar to the other SCLC lines studied (Fig. 1B). High
c-Myc mRNA levels were evident in the c-Myc ampliﬁed lines by
both RT-PCR and exon array, while expression of NANOG and POU5F1
(OCT4) are uniformally lower (Fig. 1A). There is a broad range of ex-
pression of SOX2mRNAwith the c-Myc lines tending to be low. The
three n-Myc ampliﬁed lines have detectable n-Myc protein and l-Myc
was present in the ﬁve l-Myc ampliﬁed lines.
The topoisomerase 2 inhibitor, etoposide, and the topoisomerase
1 inhibitor, topotecan, are approved for treatment of SCLC. Etoposide
and topotecan concentration response was examined in the 23 SCLC
lines (Fig. 2A). The IC50’s for etoposide ranged from 0.003 to 10 μM
and the IC50’s for topotecan ranged from 0.0015 to 1.8 μM in the 23
SCLC lines upon 96 hrs exposure to the drugs. The expression of TOP1,
TOP2A mRNA and TOP2B mRNA as well as topoisomerase 1 and
topoisomerase 1A protein were examined in the 23 SCLC lines as
well as 3 normal cell types and 2 NSCLC lines (Fig. 2B). The SCLC
lines expressed higher levels of TOP2A than did the normal cells
and the NSCLC lines. The expression of TOP1 mRNA was relatively
high in all of the cell types tested. SLFN11 expression has been as-
sociated with topoisomerase inhibitors. SLFN11 mRNA was
heterogeneously expressed in the SCLC lines. However, Myc status,
and TOP2A, TOP2B and TOP1 mRNA expression or topoisomerase
1 and topoisomerase 2 protein did not account for the nearly 3 log
range in the sensitivity of the SCLC lines to etoposide or topotecan;
however, there was a strong correlation between sensitivity to
etoposide and sensitivity to topotecan (Fig. 2C).
Gene expression for a broad spectrum of notch pathway and
related genes were present in the 23 SCLC lines (Fig. 3A). Proteo-
lytic cleavage of notch receptors by the presenilin/γ-secretase
complex is required for the activation of the notch pathway.
γ-Secretase inhibitors block notch activity [13,14]. Concentration re-
sponse experiments were carried out with two γ-secretase inhibitors,
RO429097 and PF-03084014, covering concentrations including the
clinical Cmax concentration for each compound (Fig. 3B). At con-
centrations up to 10 μM, RO429097 had little effect on the growth
of the 23 SCLC with cell growth between 90–100% of the control
at the clinical Cmax. Similarly, PF-03084014 exposure resulted in
90–100% of control cell growth at the clinical Cmax concentration.
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At the highest concentration tested, 2 of 5 l-Myc ampliﬁed SCLC lines
reached an IC50. When exposure to a concentration range of PF-
03084014was combined simultaneously with exposure to etoposide
(0.3 μM) and carboplatin (3.7 μM) in 4 representative SCLC lines ad-
ditive to sub-additive SCLC killingwas obtained as assessed by simple
Bliss additivity (Fig. 3C).
Bromodomain and extra-terminal (BET) domain proteins in-
cluding BRD2, BRD3, BRD4 and BRDT, have been associated with
acetylated chromatin and facilitate transcriptional activation [15–17].
Several reports have associated c-Myc transcription with BET
bromodomain protein activity [15,16,18]. BRD4 has beenmost clearly
associated with c-Myc activity. The gene expression for BRD1, BRD2,
BRD3, BRD4 and BRDT by the 23 SCLC lines, 3 normal cell types and
2 NSLC lines indicate that the expression of themRNA for these genes
is not highly varied in the SCLC lines (Fig. 4A). When the data were
organized by BRD4 expression, c-MYC ampliﬁed SCLC lines distrib-
uted over the range of expression. Concentration response
experiments were performed with JQ1, a known BET bromodomain
inhibitor (Fig. 4B). The mean JQ1 IC50 for the c-MYC ampliﬁed lines
was 0.47 μM, for the n-MYC ampliﬁed lines was 0.22 μM, for the
l-MYC ampliﬁed lines was 0.68 μM and for the unampliﬁed lines
was 1.9 μM. Overall, there was a trend in the MYC ampliﬁed lines
for greater sensitivity to JQ1 than the unampliﬁed lines. In a larger
series of SCLC lines, the mean JQ1 IC50 in 10 lines derived from treat-
ment naïve patients was 5.37 μM, and the mean JQ1 IC50 in 29 lines
derived from previously treated patients was 6.19 μM; this differ-
ence was not signiﬁcant. The combination of JQ1 with etoposide and
carboplatin was explored in four SCLC lines with differentMYC status
(Fig. 4C). With each of the four SCLC lines, the addition of JQ1 to
treatment with etoposide and carboplatin resulted in greater-than-
additive cytotoxicity the magnitude of which increased with
increasing JQ1 concentration. The least effect was observed with the
NCI-H720 line and the greatest effect was observed with the NCI-
2107 line. These lines were similarly responsive to JQ1 as a single
agent.
Normally, an active hedgehog pathway is required for embryo
development. Activation of the hedgehog pathway has been im-
plicated in many cancers and appears to be potentially causal in
basal cell carcinoma. mRNA for a broad spectrum of hedgehog
pathway and related genes were present in the 23 SCLC lines
(Fig. 5A). The Smo antagonists, erismodegib and vismodegib as well
as the Gli antagonists, HPI1 and SEN-450, were assessed in the 23
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SCLC lines (Fig. 5B). There was a trend for the MYC ampliﬁed lines
to be more responsive to HPI1 than the MYC unampliﬁed lines;
however, the effect was small. The same trend was observed with
SEN-450. Clinical Cmax concentrations for erismodegib and
vismodegib occurred at concentrations near the IC50s for both com-
pounds. There was a trend toward the MYC ampliﬁed lines to be
more responsive to both erismodegib and vismodegib than the MYC
unampliﬁed lines; however, the effect was small. The combina-
tion of erismodegib or vismodegib with etoposide and carboplatin
was explored in four SCLC lines with different MYC status (Fig. 5C).
With each of the four SCLC lines, the combinations were generally
additive to sub-additive.
Discussion
Drug discovery is exceptionally challenging for SCLC cancer.
Genetic and epigenetic changes including gene mutations, dele-
tions, ampliﬁcations, translocations and methylation induced gene
silencing are frequent in SCLC cell lines and tumors; however,
questions regarding the genomic stability, lack of differentiation and
absence of stromal–vascular–inﬂammatory cell compartments are
signiﬁcant issues [19]. Since biopsies are rare in SCLC diagnosis, SCLC
cell lines remain the main tool for SCLC biological characteriza-
tion and translational research. The lack of SCLC progenitor cell type
knowledge prevents identiﬁcation of SCLC gene expression changes
compared to the most appropriate normal cell [20].
Targets such as Myc have been known in SCLC for some time,
but remain diﬃcult to approach therapeutically. Other targets have
only recently become of interest. In the current study, the re-
sponse of 23 human SCLC lines of varied Myc status was assessed
to 10 targeted anticancer agents. MYC status was conﬁrmed by gene
expression and protein expression. In addition, gene expression de-
termined by exon array and by RT-PCR for lung cancer related genes,
stem-like genes, notch and hedgehog pathway genes.
c-Myc is a transcription factor which promotes cancer growth
by upregulation of a transcriptional program inﬂuencing metabol-
ic adaptation, maintenance of stem cells, cell division and survival
[21–24]. MYC is a transcriptional ampliﬁer, increasing the
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transcription of genes that are switched on in tumor cells, lym-
phocytes and stem cells. MYC effects are broad and cell-type-
speciﬁc because MYC ampliﬁes existing genetic outputs. The c-Myc
protein is implicated in physiological and pathological growth, pro-
liferation, apoptosis, metabolism, and differentiation via regulation
of numerous target genes [25]. In tumor cells expressing high c-Myc,
Myc binds in promoter regions of active genes and causes tran-
scriptional ampliﬁcation, producing increased transcripts from active
genes [26,27]. Myc overexpression stabilizes HIF1a under normoxic
conditions and enhances HIF1α accumulation under hypoxic con-
ditions [28]. c-MYC overexpression in cancer stem cells leads to
increased expression of CHK1 and CHK2 and subsequent activa-
tion of the DNA-damage-checkpoint response resulting in radio-
resistance. CHK1 and CHK2 expression loss reverses radioresistance
in cancer stem cells [29].
Direct therapeutic targeting of MYC protein remains diﬃcult. The
Myc promoter contains a guanine-rich sequence (PU27) capable of
forming quadruplex (four-stranded) DNA, which may negatively
regulate myc transcription. Exposure of Myc over-expressing cells
to an oligonucleotide encoding the genomic PU27 sequence induced
cell cycle arrest and death [30]. Pharmacologically interfering with
the bromodomain and extraterminal (BET) proteins depletes MYCN
in cells resulting in cytotoxicity [31]. The bromodomain and
extraterminal (BET) protein Brd4, described as a general transcrip-
tional regulator, recruits transcriptional regulatory complexes
to acetylated chromatin [32,33]. The therapeutic effects of
bromodomain inhibitors have been attributed to a speciﬁc set of
downstream target genes whose expression is disproportionately
sensitive to pharmacological targeting of BET proteins. Brd4 engages
in direct regulatory interactions with several DNA-binding tran-
scription factors to inﬂuence their function [34]. BET inhibitors
engage the bromodomain pocket in a competitive manner with
acetylated peptide binding, thereby causing the displacement of BET
pro-proteins from chromatin in cells exposed to these compounds.
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The bromodomain reader protein family has a role in translating
histone modiﬁcations with transcriptional consequences; thus,
bromodomain proteins are potential therapeutic targets [35–37].
The BET bromodomain inhibitor JQ1 was more effective in the MYC
ampliﬁed lines, and, interestingly, JQ1 in combinationwith etoposide
and carboplatin resulted in greater-than-additive cytotoxicity even
in the MYC unampliﬁed cell line tested (Fig. 4B and C). There is de-
veloping evidence that factors in addition to MYC expression may
be important in the response to the BET bromodomain class of com-
pounds in SCLC and other cancers in culture and in xenografts
[38,39]. Several BET bromodomain inhibitors are currently in early
clinical trial in hematologic and solid malignancies.
The mainstays of SCLC standard of care are the toposiomerase
II inhibitor etoposide and the topoisomerase I inhibitor topotecan.
The response of the 23 SCLC lines to these drugs was highly het-
erogeneous and unrelated to the Myc status of the lines (Fig. 2A).
The expression of the TOP2A and 2B genes as well as the TOP1 gene
expression were determined in the 23 SCLC lines and 3 normal cell
types and 2 non-small cell lung lines. The expression of TOP2A was
lower in the normal cells and non-small cell lung cancer lines than
in the SCLC lines while the expression of TOP2B and TOP1was similar
in all of the cells (Fig. 2B). Neither the gene expression nor the protein
expression of the topoisomerases reﬂected the great heterogene-
ity of the response of the SCLC lines to etoposide and topotecan.
However, there was a very strong correlation between the re-
sponse of the SCLC lines to etoposide and topotecan which could
not be accounted for in the gene expression data (Fig. 2C).
The notch pathway is an intercellular signaling mechanism re-
quired for embryonic development. Key factors in the pathway are
notch transmembrane receptors and delta (or delta-like) and jagged
ligands. Mutations in notch pathway members are rare in SCLC
and studies indicate that a hyperactive notch pathway may sup-
press SCLC and down-regulate ASCL1 expression [40–42]. The SCLC
lines were not responsive to γ-secretase inhibitors alone or in com-
bination with etoposide and carboplatin (Fig. 3B and C). The
Hedgehog signaling pathway is one of the key regulators of embryo
development. The hedgehog pathway regulates the survival and
proliferation of several tissue progenitor and stem populations pro-
moting the expression of several well-known stem cell and
proliferative genes, including genes encodingMYC, cyclin D1, insulin-
like growth factor 2 (IGF2) and BMI. In some cancers, dysregulation
of hedgehog pathway signaling in a stem cell population can explain
tumor formation [43]. The highly aggressive nature of SCLC sug-
gests that this disease may have an elevated stem cell fraction.
Neither the Gli inhibitors nor the Smo inhibitors had marked effects
on the SCLC as single agents or in combination with etoposide and
carboplatin (Fig. 5B and C). Trends associated with MYC status were
quite weak for both the notch pathway inhibitors and the hedge-
hog pathway inhibitors.
Recurrent SCLC is among the most recalcitrant cancers. Addi-
tional drug development efforts focused on achieving clinical beneﬁt
in this disease are a high priority.
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